ArticleJournal of the American Statistical Association2026
Enhanced Marginal Sensitivity Model and Bounds.
Article in Journal of the American Statistical Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Sensitivity analysis is important to assess the impact of unmeasured confounding in causal inference from observational studies. The marginal sensitivity model (MSM) provides a useful approach in quantifying the influence of unmeasured confounders on treatment assignment and leading to tractable sharp bounds of common causal parameters. In this paper, to tighten MSM sharp bounds, we propose the enhanced MSM (eMSM) by incorporating another sensitivity constraint which quantifies the influence of unmeasured confounders on outcomes. We derive sharp population bounds of expected potential outcomes under eMSM, which are always narrower than the MSM sharp bounds in a simple and interpretable way. We further discuss desirable specifications of sensitivity parameters related to the outcome sensitivity constraint, and obtain both doubly robust point estimation and confidence intervals for the eMSM population bounds. The effectiveness of eMSM is also demonstrated numerically through two real-data applications. Our development represents for the first time a satisfactory extension of MSM to exploit both treatment and outcome sensitivity constraints on unmeasured confounding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.